|
US4082845A
(en)
|
1977-04-25 |
1978-04-04 |
Merck & Co., Inc. |
3-(1-Piperazinyl)-pyrido[2,3-b]pyrazines
|
|
JPS5665863A
(en)
|
1979-10-31 |
1981-06-03 |
Tokyo Organ Chem Ind Ltd |
Novel aniline derivative, its preparation and pesticide containing the same
|
|
JPS5738777A
(en)
|
1980-08-19 |
1982-03-03 |
Sogo Yatsukou Kk |
2-sufanilamidopyrathyn derivative
|
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
|
US5643755A
(en)
|
1994-10-07 |
1997-07-01 |
Regeneron Pharmaceuticals Inc. |
Nucleic acid encoding tie-2 ligand
|
|
US5879672A
(en)
|
1994-10-07 |
1999-03-09 |
Regeneron Pharmaceuticals, Inc. |
Tie-2 ligand 1
|
|
EP0783572B1
(en)
|
1994-09-22 |
2005-04-27 |
Licentia Ltd. |
Promoter for the receptor tyrosine kinase, tie
|
|
WO1998004689A1
(en)
|
1995-07-31 |
1998-02-05 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate disease
|
|
US6218529B1
(en)
|
1995-07-31 |
2001-04-17 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
|
|
AU7340096A
(en)
*
|
1995-11-07 |
1997-05-29 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
|
|
ZA971896B
(en)
|
1996-03-26 |
1998-09-07 |
Du Pont Merck Pharma |
Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
|
|
WO1998013350A1
(en)
|
1996-09-25 |
1998-04-02 |
Zeneca Limited |
Qinoline derivatives inhibiting the effect of growth factors such as vegf
|
|
US6030831A
(en)
|
1997-09-19 |
2000-02-29 |
Genetech, Inc. |
Tie ligand homologues
|
|
NZ503432A
(en)
|
1997-09-26 |
2002-11-26 |
Zentaris Gmbh |
Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
|
|
GB9721437D0
(en)
|
1997-10-10 |
1997-12-10 |
Glaxo Group Ltd |
Heteroaromatic compounds and their use in medicine
|
|
PL195808B1
(pl)
*
|
1997-12-22 |
2007-10-31 |
Bayer Corp |
Moczniki arylowe, kompozycja je zawierająca i ichzastosowanie
|
|
US20010053946A1
(en)
*
|
1998-09-04 |
2001-12-20 |
R. R. Donnelley & Sons Company |
System for controlling feeders of a package assembly apparatus
|
|
KR100609800B1
(ko)
|
1998-12-16 |
2006-08-09 |
워너-램버트 캄파니 엘엘씨 |
Ｍｅｋ 저해제를 사용한 관절염 치료 방법
|
|
ATE292462T1
(de)
|
1999-01-07 |
2005-04-15 |
Warner Lambert Co |
Behandlung von asthma anhand von mek-inhibitoren
|
|
US6797823B1
(en)
*
|
1999-01-22 |
2004-09-28 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives
|
|
AU3475900A
(en)
|
1999-01-29 |
2000-08-18 |
University Of Akron, The |
Polyimides used as microelectronic coatings
|
|
EP1202726A2
(en)
|
1999-07-16 |
2002-05-08 |
Warner-Lambert Company Llc |
Method for treating chronic pain using mek inhibitors
|
|
CN1391562A
(zh)
*
|
1999-09-21 |
2003-01-15 |
阿斯特拉曾尼卡有限公司 |
用作药物的喹唑啉衍生物
|
|
GB2356398A
(en)
|
1999-11-18 |
2001-05-23 |
Lilly Dev Ct S A |
Preparation of arylsulfamides
|
|
ES2245955T3
(es)
|
1999-12-21 |
2006-02-01 |
Sugen, Inc. |
7-aza-indolin-2-onas 4-sustituidas y su utilizacion como inhibidores de proteina-quinasa.
|
|
US6492529B1
(en)
|
2000-01-18 |
2002-12-10 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Bis pyrazole-1H-pyrazole intermediates and their synthesis
|
|
WO2002044156A2
(en)
|
2000-11-29 |
2002-06-06 |
Glaxo Group Limited |
Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
|
|
KR20020096367A
(ko)
|
2001-06-19 |
2002-12-31 |
주식회사 티지 바이오텍 |
관절염 예방 또는 치료제 및 그것의 스크리닝 방법
|
|
CA2471114C
(en)
|
2001-12-21 |
2012-03-20 |
The Wellcome Trust |
Mutant b-raf polypeptide and a use thereof in the diagnosis of cancer
|
|
US20030180226A1
(en)
|
2002-01-23 |
2003-09-25 |
Haughton Pauline A. |
Anti-bacterial sneeze spray
|
|
CA2493575A1
(en)
|
2002-08-09 |
2004-02-19 |
Christopher J. Dinsmore |
Tyrosine kinase inhibitors
|
|
EP1604037A1
(en)
|
2003-03-20 |
2005-12-14 |
Universite Catholique De Louvain |
Medical use of ras antagonists for the treatment of capillary malformation
|
|
DE602004024988D1
(de)
|
2003-06-13 |
2010-02-25 |
Novartis Ag |
2-aminopyrimidin-derivate als raf-kinase-hemmer
|
|
RU2006129307A
(ru)
|
2004-02-13 |
2008-02-20 |
Пфайзер Продактс Инк. (Us) |
Терапевтические комбинации атипичных нейролептиков с антагонистами кортикотропин-рилизинг фактора
|
|
EP1724268A4
(en)
|
2004-02-20 |
2010-04-21 |
Kirin Pharma Kk |
COMPOUNDS WITH TGF-BETA-HEMMENDER EFFECT AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
|
|
TW200616974A
(en)
|
2004-07-01 |
2006-06-01 |
Astrazeneca Ab |
Chemical compounds
|
|
AU2005278959A1
(en)
|
2004-08-31 |
2006-03-09 |
Astrazeneca Ab |
Quinazolinone derivatives and their use as B-Raf inhibitors
|
|
BRPI0518126A
(pt)
|
2004-10-15 |
2008-10-28 |
Astrazeneca Ab |
composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença ou condição
|
|
GB0423554D0
(en)
|
2004-10-22 |
2004-11-24 |
Cancer Rec Tech Ltd |
Therapeutic compounds
|
|
GB0428082D0
(en)
*
|
2004-12-22 |
2005-01-26 |
Welcome Trust The Ltd |
Therapeutic compounds
|
|
EP1835934A4
(en)
|
2004-12-23 |
2010-07-28 |
Deciphera Pharmaceuticals Llc |
ENZYME MODULATORS AND TREATMENTS
|
|
CA2629468A1
(en)
|
2005-11-15 |
2007-05-24 |
Bayer Pharmaceuticals Corporation |
Pyrazolyl urea derivatives useful in the treatment of cancer
|
|
CA2631746A1
(en)
|
2005-12-01 |
2007-06-07 |
Bayer Healthcare Llc |
Urea compounds useful in the treatment of cancer
|
|
CN101365682A
(zh)
|
2005-12-08 |
2009-02-11 |
千禧药品公司 |
具有激酶抑制活性的双环化合物
|
|
US7989461B2
(en)
|
2005-12-23 |
2011-08-02 |
Amgen Inc. |
Substituted quinazolinamine compounds for the treatment of cancer
|
|
CN101040720A
(zh)
|
2006-03-24 |
2007-09-26 |
沈华立 |
一种豆腐干的五香麻辣卤汤液
|
|
US20090149484A1
(en)
*
|
2006-04-18 |
2009-06-11 |
Astrazeneca Ab |
Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them
|
|
WO2007125330A1
(en)
|
2006-04-26 |
2007-11-08 |
Cancer Research Technology Limited |
Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
|
|
EP1992628A1
(en)
|
2007-05-18 |
2008-11-19 |
Glaxo Group Limited |
Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
|
|
US8227603B2
(en)
|
2006-08-01 |
2012-07-24 |
Cytokinetics, Inc. |
Modulating skeletal muscle
|
|
WO2008044688A1
(en)
|
2006-10-11 |
2008-04-17 |
Daiichi Sankyo Company, Limited |
Urea derivative
|
|
EP2446903B1
(en)
|
2006-11-20 |
2019-10-09 |
President and Fellows of Harvard College |
Compositions for treating itch
|
|
NZ582390A
(en)
|
2007-07-10 |
2012-05-25 |
Neurim Pharma 1991 |
Cd44 splice variants in neurodegenerative diseases
|
|
CA2709257C
(en)
|
2007-12-19 |
2016-12-13 |
Cancer Research Technology Limited |
Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
|
|
GB0807609D0
(en)
|
2008-04-25 |
2008-06-04 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
EP2288922B1
(en)
|
2008-05-08 |
2016-08-17 |
University of Utah Research Foundation |
Sensory receptors for chronic fatigue and pain and uses thereof
|
|
GB0818033D0
(en)
|
2008-10-02 |
2008-11-05 |
Respivert Ltd |
Novel compound
|
|
MX2011003553A
(es)
|
2008-10-02 |
2011-05-25 |
Respivert Ltd |
Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38.
|
|
JP2012511563A
(ja)
|
2008-12-11 |
2012-05-24 |
レスピバート・リミテツド |
ｐ３８ＭＡＰキナーゼ阻害剤
|
|
GB0905955D0
(en)
|
2009-04-06 |
2009-05-20 |
Respivert Ltd |
Novel compounds
|
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
|
AU2010289794B2
(en)
|
2009-08-24 |
2014-10-02 |
Genentech, Inc. |
Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels
|
|
GB0918249D0
(en)
|
2009-10-19 |
2009-12-02 |
Respivert Ltd |
Compounds
|
|
GB0921731D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Theraputic uses
|
|
GB0921730D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Method of treatment
|
|
ES2469367T3
(es)
|
2010-02-01 |
2014-06-18 |
Cancer Research Technology Limited |
1-(5-Terc-butil-2-fenil-2H-pirazol-3-il)-3-[2-fluoro-4-(1-metil-2-oxo-2,3-dihidro-1H-imidazo[4,5-b]piridin-7-iloxi)-fenil]-urea y compuestos relacionados y su uso en terapia
|
|
GB201005589D0
(en)
|
2010-04-01 |
2010-05-19 |
Respivert Ltd |
Novel compounds
|
|
WO2011124930A1
(en)
|
2010-04-08 |
2011-10-13 |
Respivert Limited |
P38 map kinase inhibitors
|
|
EP2556067B1
(en)
|
2010-04-08 |
2016-02-24 |
Respivert Limited |
Pyrazolyl ureas as p38 map kinase inhibitors
|
|
JP5973426B2
(ja)
|
2010-06-17 |
2016-08-23 |
レスピバート・リミテツド |
Ｐ３８ｍａｐｋ阻害剤を含む呼吸器用製剤
|
|
GB201010196D0
(en)
|
2010-06-17 |
2010-07-21 |
Respivert Ltd |
Methods
|
|
GB201010193D0
(en)
|
2010-06-17 |
2010-07-21 |
Respivert Ltd |
Medicinal use
|
|
WO2012008564A1
(ja)
|
2010-07-16 |
2012-01-19 |
協和発酵キリン株式会社 |
含窒素芳香族複素環誘導体
|
|
UY33337A
(es)
|
2010-10-18 |
2011-10-31 |
Respivert Ltd |
DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
|
|
WO2012149547A1
(en)
|
2011-04-28 |
2012-11-01 |
Duke University |
Methods of treating hemoglobinopathies
|
|
AU2012273004B2
(en)
|
2011-06-23 |
2017-04-13 |
Mycovia Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
WO2013001372A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of Oslo |
Methods and compositions for inhibition of activation of regulatory t cells
|
|
CA2845571A1
(en)
|
2011-09-01 |
2013-03-07 |
Novartis Ag |
Use of organic compound for the treatment of noonan syndrome
|
|
EP2578582A1
(en)
|
2011-10-03 |
2013-04-10 |
Respivert Limited |
1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
|
|
CA2846222C
(en)
|
2011-10-03 |
2020-07-07 |
Respivert Limited |
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1- yl) ureas as p38 map kinase inhibitors
|
|
GB201214750D0
(en)
|
2012-08-17 |
2012-10-03 |
Respivert Ltd |
Compounds
|
|
WO2014033446A1
(en)
|
2012-08-29 |
2014-03-06 |
Respivert Limited |
Kinase inhibitors
|
|
GB201215357D0
(en)
|
2012-08-29 |
2012-10-10 |
Respivert Ltd |
Compounds
|
|
WO2014033447A2
(en)
|
2012-08-29 |
2014-03-06 |
Respivert Limited |
Kinase inhibitors
|
|
US9783556B2
(en)
|
2012-08-29 |
2017-10-10 |
Respivert Limited |
Kinase inhibitors
|
|
US9732063B2
(en)
|
2012-11-16 |
2017-08-15 |
Respivert Limited |
Kinase inhibitors
|
|
EP2970190A1
(en)
|
2013-03-14 |
2016-01-20 |
Respivert Limited |
Kinase inhibitors
|
|
JO3279B1
(ar)
|
2013-03-15 |
2018-09-16 |
Respivert Ltd |
مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
|
|
US9771353B2
(en)
|
2013-04-02 |
2017-09-26 |
Topivert Pharma Limited |
Kinase inhibitors based upon N-alkyl pyrazoles
|
|
KR102283883B1
(ko)
|
2013-04-02 |
2021-07-29 |
옥슬러 액퀴지션즈 리미티드 |
키나제 저해제
|
|
GB201320729D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
US9890185B2
(en)
|
2013-12-20 |
2018-02-13 |
Respivert Limited |
Urea derivatives useful as kinase inhibitors
|
|
CA2938924C
(en)
|
2014-02-14 |
2023-01-31 |
Respivert Limited |
Pyrazolyl-ureas as kinase inhibitors
|
|
MA40774A
(fr)
|
2014-10-01 |
2017-08-08 |
Respivert Ltd |
Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
|
|
WO2016051186A1
(en)
|
2014-10-01 |
2016-04-07 |
Respivert Limited |
N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors
|